Strs Ohio Buys Shares of 54,700 AngioDynamics, Inc. $ANGO

Key Points

• Strs Ohio made a significant investment of $514,000 in AngioDynamics, acquiring 54,700 shares, which represents 0.13% ownership of the medical instruments company.
• Various institutional investors have increased their stakes in AngioDynamics, with GAMMA Investing LLC boosting their position by 1,281.4% in the 1st quarter.
• AngioDynamics has received multiple "buy" ratings from analysts and has a current average price target of $19.00, suggesting positive market sentiment about its future prospects.

Strs Ohio bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 54,700 shares of the medical instruments supplier's stock, valued at approximately $514,000. Strs Ohio owned about 0.13% of AngioDynamics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Jane Street Group LLC grew its holdings in AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier's stock valued at $439,000 after buying an additional 34,054 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier's stock valued at $2,434,000 after purchasing an additional 22,658 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of AngioDynamics in the first quarter valued at $939,000. Cubist Systematic Strategies LLC raised its stake in shares of AngioDynamics by 71.8% in the first quarter. Cubist Systematic Strategies LLC now owns 232,473 shares of the medical instruments supplier's stock valued at $2,183,000 after purchasing an additional 97,123 shares in the last quarter. Finally, Armistice Capital LLC boosted its stake in AngioDynamics by 140.1% during the first quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier's stock worth $19,663,000 after buying an additional 1,222,000 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Lake Street Capital began coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They set a "buy" rating and a $24.00 price target for the company. Wall Street Zen upgraded shares of AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a report on Wednesday, July 16th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, AngioDynamics presently has an average rating of "Buy" and a consensus price target of $19.00.

AngioDynamics Price Performance

Shares of AngioDynamics stock traded down $0.04 during midday trading on Monday, hitting $10.73. 287,471 shares of the company were exchanged, compared to its average volume of 366,381. The firm has a market cap of $435.96 million, a P/E ratio of -12.93 and a beta of 0.64. AngioDynamics, Inc. has a 52 week low of $5.83 and a 52 week high of $13.50. The firm has a 50 day simple moving average of $9.57 and a 200-day simple moving average of $9.65.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09. The business had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.AngioDynamics's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.06) EPS. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. Equities research analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.